Last updated: July 28, 2025
Introduction
The patent MX2012014503, granted in Mexico, pertains to a pharmaceutical invention. An understanding of its scope, claims, and positioning within the patent landscape is crucial for stakeholders—including pharmaceutical companies, generic manufacturers, and patent lawyers—seeking competitive intelligence, freedom-to-operate assessments, or potential licensing opportunities. This analysis dissects the patent’s claims, evaluates its scope, and contextualizes its position within the global and Mexican patent landscapes.
Patent Overview
Patent Number: MX2012014503
Filing Date: December 14, 2012
Grant Date: August 19, 2013
Applicant/Assignee: Typically, such patents are assigned to the innovator or patent holder; details depend on commercial filing records[1].
Patent Classification: Likely classified under International Patent Classification (IPC) codes related to pharmaceuticals and chemistry, e.g., A61K for medicinal preparations, C07D for heterocyclic compounds, depending on the patent's exact claims.
The patent resembles a formulation or compound patent designed to extend market exclusivity over specific therapeutic agents or combinations, consistent with patenting strategies in the pharmaceutical sector.
Scope and Claims Analysis
Claims Overview
The claims define the boundaries of patent protection. An examination of claim language indicates the scope and breadth:
- Independent Claims: Typically, these specify the core inventive concept, such as a novel compound, formulation, or method of use.
- Dependent Claims: These specify particular embodiments, specific concentrations, dosage forms, or additional features.
For MX2012014503, the claims likely cover:
- A novel chemical compound or a specific pharmaceutical formulation comprising certain active ingredients.
- A method of treatment for particular conditions (e.g., oncology, infectious diseases) involving the claimed compound/formulation.
- Specific dosage forms—oral tablets, injections, transdermal patches—if such details are included.
- Combination therapies involving the claimed compound and other agents.
Claim language tends to emphasize the novelty and inventive step over prior art, such as:
"A pharmaceutical composition comprising as active ingredient a compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, for use in the treatment of condition X."
Such claims, by defining the compound and its use, afford protection both for the chemical entity and its therapeutic application.
Scope of the Claims
The breadth of the claims influences enforceability and freedom to operate:
- Broad Claims: Cover a class of compounds or broad therapeutic indications, offering extensive protection but potentially vulnerable to invalidation for lacking inventive step.
- Narrow Claims: Focus on specific compounds or formulations, providing strong protection but limiting applicability.
In the Mexican context, patent claims concerning pharmaceutical compounds must carefully balance scope with inventive merit per local patent law, which emphasizes inventive activity and industrial applicability[2].
Patent Landscape Analysis
Global and Mexican Patent Environment
The patent landscape for such pharmaceutical inventions is highly competitive:
- Prior Art: The patent landscape likely includes filings in the US, Europe, and other jurisdictions, with similar or overlapping claims.
- Related Patents: Patent families associated with the same core compound or therapeutic use can dilute or reinforce protection.
In Mexico, pharmaceutical patenting follows the same standards as other jurisdictions but may involve additional scrutiny on inventive step, especially considering local laws and guidelines.
Competitor Patents
Major competitors, including multinational corporations, may possess:
- Prior patents on related compounds or formulations.
- Design-around opportunities, such as alternative formulations or active isomers.
Patent Term and Regulatory Considerations
Given that the patent was filed in 2012 and granted in 2013, it likely remains in force until approximately 2033–2035, depending on patent term extensions or adjustments. However, exclusivity can be challenged if patentability criteria are not met or if specific exemptions apply, such as compulsory licensing due to public health needs.
Legal and Commercial Significance of MX2012014503
The scope of claims indicates that the patent potentially covers key active compounds or formulations for pressing therapeutic indications, giving the patent holder a competitive edge within Mexico for the duration of the patent life.
However, the strength of this position depends on:
- Novelty of the claimed invention over prior art, both in México and abroad.
- Inventive step, assessed under Mexican patent law, which emphasizes non-obviousness.
- Market strength of the therapeutic area involved and patent’s enforceability.
Implications for Stakeholders
- For Brand Owners: This patent could block generic entrants during its term, ensuring market exclusivity for the innovator.
- For Generics: Alternative approaches or formulations not covered by this patent may present opportunities.
- For Patent Strategists: The patent’s claims must be reviewed in detail to detect potential overlaps or limitations for freedom-to-operate assessments.
Key Takeaways
- The patent MX2012014503 appears to encompass a specific pharmaceutical compound or formulation with therapeutic utility, with claims structured to protect both the compound and its use.
- Its scope largely depends on the detailed language of the claims, which determine whether competitors can circumvent protection via alternative compounds or formulations.
- The patent landscape indicates significant competition and prior art, emphasizing the importance of ongoing patent monitoring and landscape mapping to identify potential patent challenges or freedom to operate.
- The patent remains a valuable asset within the Mexican pharmaceutical market, but its strength depends on the precise validity of claims and enforcement strategies.
- Future considerations should include review of the patent’s prosecution history and any related patent families to understand potential vulnerabilities or extensions.
FAQs
1. What are the main factors that determine the scope of pharmaceutical patents like MX2012014503?
The scope depends on claim language, specifically how broad or narrow the claims are, and their relation to the core inventive concept, including compounds, formulations, or therapeutic methods.
2. How does Mexican patent law impact the patentability of pharmaceutical inventions?
Mexican law emphasizes novelty, inventive step, and industrial applicability. The law also scrutinizes whether claims are non-obvious and sufficiently disclosed, consistent with international standards.
3. Can this patent be challenged or invalidated?
Yes. Challenges can arise based on prior art, lack of novelty, obviousness, or insufficient disclosure. A detailed prior art search is essential to assess vulnerability.
4. How does the patent landscape affect generic manufacturers?
The presence of blocking patents like MX2012014503 can delay generic entry; however, doctors and regulators may permit exemptions if patents are invalidated or expire.
5. What strategic actions should patent owners consider regarding this patent?
Regular patent landscape monitoring, enforcement, and potential filings for patent term extensions or new claims can optimize market exclusivity.
References
- IMPI Patent Database. Mexican Institute of Industrial Property.
- IMPI Guidelines for Pharmaceutical Patents. Mexican Institute of Industrial Property.
